!"#$% &!'(') *!'+ $&,"-.&% / 01 )2% % 6!( 78

Transcription

1 () :!"#$% &!'(') *!'+ $&,"-.&% / 01 )% % 6!( 78 %(" /' M.D. M.D. M.D. M.D. M.Sc.!" * 1 Ph.D.. %)'% * %)F *'"G"6.F9"< " ($) *.A,:0-&E= *(D@)...% /" :6(= >4?@ AB0% * :/9: ; < 85/10/19 :/5 549O >H@% I' 85/9/18 :A,6 LH% /5 MN' I' 85/6/8 :4& >H@% I' /H8 &! "# $% :& /!,0 1!&. ' ' ()* +,* - * "! ", * # "6#, 7 8/9 : 0 ; <* =,,>0 $&* $ "0 $! - 0?@ ; & < 7 A#* "0.< #B C * $ A#* 0 #*0, (L)... B $ 75 "0 DE& 0 * $ 0 1F GH :?( ( 0 $ 40! T$ U0 +%.(0 ', 5) R $ WA$. " ' "/* " Visual Analysis Score (VAS)?V G 7 )$ R0 0 ' 0 R ' / 10 0 A#* 4#A* 40 0 ' : <#B& 0 ' $ DE& 1F Z 1 0 R ' / 10 0 $ 4#A* R$ 0 ' 0 0 R ' / 5 0 #*0, ", \- " C% "0 Z % =, 0 0 "/ % W%. * [ E. (p< 0/05) * % " +,* Z W% 0 ' $, VAS 0 :$ #*0, 0 ' 18.(?' G0 (G^ (:0 \- " C% "0 Z % G0 (6. 'G7 ` V $ 0 ' 6 0 A#* 0 ' 14 " " +,* 0, (p>0/05) "0# \ B& ;a& A#* #B #*0, bd c^d 5e +,* <9 / $ * G^ (p< 0/05) * - VAS 0.( " * ;a& 5e "0 0 (# (p<0/05)!& 0 GH A#* 0 #*0, 6?@ ;!& :@* "0 $ $ c #*0, '* [ E 0 ' * "?!. +,* " 6 ;a& A#* bd. #*0, A#* $ $)G$ :.& 9;A( 6(75.&45.1/ 0* +,-.&'() ($)...! -1 majidshohrati@yahoo.com : (; ($)... 9 ($) / 0* +,-.&'() =* -

2 %:G- & )F6,"Q 10 0 ' #D : ",0 ;a& se " # "6' H 0 H 1 # ' 7 (F A#* 6AG0!&.[1 0]!0 1: 6 5e F!0 0?* 0E & 0 D d "t^d 0 0 <# u@? D F& ",0 U `@ se & #*0, $ "0 $?@ ; & < 7 GH.< #B #& A#* 0 $ 7& & %4 C * $ 0 G 7* 1F GH 1844$ 4 (L)... B $! ' 6 7 (^0 - "B$ * 75 &.($ R- v$% : o/@ "6 0 He 4 *. GH 0 (w ", $ s $% Z#$ "6 0 D ' e " 0 (m& k' +D "6?*0 V GH 4 * =,. ' x GH 0 ($#^ C?$ % /$0 GH +% 1E@? 48 w*^ [] 0 (;,?$ % o) 17. ' $m 5^ "/* D ' c " 0 y$ 17- +% VAS (Visual Analysis Score) =,..[] " ' " /* GH U0 0 ' Z : <#B& 0 ' $ DE& s e R0 0 ' 0 5 mg0 #*0, s e A#* 4#A* R$ 0 ' mg 0 $ % W%. * [ E Z mg D ' e 0,,. $m \- 6 7 VAS. e,?$ % Z 4 - ", $ % W% Z =,.D ' e \- bd "* 8E& 184 4$ GH GH U0.(D ' e (L)... B % R/ C? /, "! 5/ f 1d? & * ($ ($% EE@ ' ()* +,* - [1] ' ' ZgGD 5 Z =,.[-4].[5] ($ $% ", - " H ' 6! G0 [6] ($6& ",c& \& : $ )G$.[7]? 7 - i & 4 & )G0 % "6G/$ dg7 5 Z 0 [8] k' j 0 >)G ($% (D "6G/$ ^ /!. 0 ^ - i ' < & $ )G$ * [10 9] R & 7 R0B V '.[11] 5 <B# Z#*& ; (/ \& `#m ' "* 6& 6& * H - & *n *, G0. $% ", (6! 0 o/@ "60 *& "6 5 \& * D ' e +7 : *& *,0 /!.[1] ^ 0 d D ' e )$ *,' ^ 0 : 1F D0 &7! 5G *,>0 $&* [ E #' 0 ; <* ' =, 0 ($%.[1] - <# "# *!& & ;p [14 6] ($ #, ",& "$7 7 D '* 7 " *& * 6 #*0,,0 <e 5#.#,,#, "6/&0 % * <, 0!& +% 6G$ (/ q[15] F& $ "0 C$ 6? 1 ; 0 "j $ &* rh$ +,* 0 'G7 ` -' ) "* E 0.[17 16] ($ 0m 6 7 #' -& (", $ c H 1 (# ' 7 ",#, 7 R0 5# )$ * - " *! * "07` 0 0 Z [ E,0. ' e [18] "j $ R 0 <e 5# (# * 0 D.[19] "? k%

3 11!"#$% &!'(') *!'+ $&,"-.&% / 01 )% %(" /' : $ 0 p<0/001 : #*0, p<0/001:a#*)..(1-40!) (p<0/001 *^ bd 0 ' $ W% 1 "#B 8& &. 0 ' $ "7 [d!0 * A#* '* [ E 1 y$ * C? $ '*[ E 0 C a& VAS $ Z* bd [d!0.(p=0/019).(p=0/04) ' ` 5 B& y$& '! 0 ' 6 A#* 0 ' 14 (sedation) 'G7.(p = 0/8) #*0, 0 ' 18 0 $. (p = 0/974),? 0 ', -' & 6& " C% "0 "6 w* 0 * 6 * U0 B " \ B& (?' V \- " C% "0 W% y$. 0 ' 1/81±7/ A#* 0 ' $ 0 ' 0 /14±7/1 #*0, [d U0 (# * /76±7/14 "0 "6 VAS.(1 40!) ( " Z U0 " ' B " C% 0 ' 61/60±17/ $ 0 ' * " #*0, 0 ' 0 6/59±19/11 A#* +% (# 6 7 [d * $ 6/6±/68.(1 40!) (# "7 }mg G^ "/* GH " 5* r:& : 7 z " +7 ",0 1F & $ 7 =,. (D (:. C T& LG Z% 0 ', 0 0 SPSS 1 "7 D R "/$0 1d "/* (6 G 7 Chi-square 0 ANOVA ",7 )$.(D ' e "7 D' [ E 0 Z 1 75 & +,0{% (D 0 ' 4$ 4/ ±5/4 $ y$. * * [ E 0 ' 44/± 6/ A#* * #*0, '* [ E 0 ' 4$ 41/1 ± 6/ 0 $. GH,.(p =0/756) "0 U0 5e y$ 8& & #*0, 0 $ A#* "6,0 '.(p=0/666) 4/59±/4 0 /56±4/60 /67±4/45 GH U0 6,0 ' VAS B C 69/±18/6 0 64/6±16/9 68/90±17/ 8& & y$ 0 8& (D Z 1 W%.(p=0/560) A#* * [ E 0 ' $ 4/48±4/06 8& & #*0, 0 $ y$. (1 ) $ 5/86 ± /1 0 7/64±/ /08±18/8 /10±14/67 8& & VAS +,*,? * (D +,* 40/64±0/94 0 $, "* (D VAS 0 /!') /#' /$)( < /'%(.o/@ ", 1 [ m 0 C :1 6(&C $'/( ± (/)! $)/%) ± (/$' $$/)! ± (/') /%'# )/ ± )(/$$ '(/! ± $/%& '!/!% ±!/ '#/% ± $/)' /)&!/% ± )%/%' $$/# ±!/ $$/( ±!/!# $!/#& ± $/!' /!/$ ± )/$& +*,-./ 0*1 p value $ '/&# ± )&/)) $'/) ± )!/( %/& ± )(/$' +* VAS /)% $/$ ± ''/%!/! ± '/&! &/'$ ± )%/$ 0*1 /&!& /!$ /# p value

4 %:G- & )F6,"Q * 0*1 1 c^d 5e +,* $ '* [ E 9 0 ;a& * * - * ($!& 8G!.[] ($ C "6' 5^ "/* VAS 0 0, 1 j& p R*, C,? 0 " \d*. " C (mf {0 'G7 `! ": - []? C 1GH (# GH $ "GH $ #*0, - (#.[4] R- 1GH $? '* [ E : - /* (6.,?,0 $? #*0, A#* 0 #*0, "0 0? \ B& ;!& A#* $ c #*0,? * $! R0B * < G. C "0 0 ;a& 0 6'7+% & g 5 DNA =,.[5] ;p o/@,0 U (0B - i & $ )G$.[6] VAS." ' o/@ 0 0 Z)& 1 C 1 j& : * 0*1 R 4 6#, 7 ~$0 o * BBm 0 EE@ "# * c #, 8$ `@ Z.[4] D C e 47 $ 0 ' ",0 /! )/@ y 8$ "0 Z `@ " <9 /. D ' c : - g&% 0 g 5 6#, 7 ;a& )/@ 1BBm& 0 1GH * "* a& L R=, ($ R- 6& G.[5-7] 1Em )$ (6! He v$% 6#, 7 t R0B!& 5e ;a& 6' 0 [7] z H R0B se 0V * &.[9 8] ($?@ ; $ GH /F [, (6 c,0 $ )$ +,* 0,0.[0] 6 7! 5G,>0 $&* "0# \ B&?@ ; #*0, GH VAS 0 +,* $? 0 A#* 80% * [ E #*0, *,0 '.(? 1GH * G^,? 6 65% 0d.[1] ' B *

5 1!"#$% &!'(') *!'+ $&,"-.&% / 01 )% %(" /' %,O & ):0 R- * " e < * $ 0 / "e7 `!. "C$A$ F 1# 0 ", +,0{% 0 $, 0 % "/* ($ R {0 (L)... B % R/ C? ",- 1- Woodruff PW, Higgins EM, Vivier AW, Wessely S. Psychiatric illness in patients referred to a dermatology-psychiatry clinic. Gen Hosp Psychiatry, 1997; 19: Weldon DR.Quality of life in patients with urticaria. Allergy Asthma Proc, 006; 7: Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol, 006: 154: Duque MI, Yosipovitch G, Chan YH, Smith R, Levy P. Itch, pain, and burning sensation are common symptoms in mild to moderate chronic venous insufficiency with an impact on quality of life. J Am Acad Dermatol, 005; 5: Schmack I, Kruse FE, Bauer A, Volcker HE, Dithmar S. Neurodermatitis, A risk factor for the development of squamous cell carcinoma. Ophthalmolog, 006; 10: Weisshaar E, Dunker N, Domrose U, Neumann KH, Gollnick H. Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT receptor blocker and antihistaminic therapy. Clin Nephrol 00, 59: Steven L. Jinks and E. Carstens. Responses of Superficial Dorsal Horn Neurons to Intradermal Serotonin and Other Irritants: Comparison with Scratching Behavior. The Journal of Neurophysiology 00; 87: Kehe K, Szinicz L. Medical aspects of sulfur mustard poisoning. Toxicology, 14: Willems, JL.Clinical management of mustard gas casualties. Ann Med Mil Belg 1989; : S1-S Khateri S, Ghanei M, Soroush M, and Haines D. Incidence of lung, eye and skin lesions as late complications in 4,000 Iranians with wartime exposure to mustard agent. J Occ Environ Med 00; 45: Bullman T, Kang H. A fifty year mortality followup study of veterans exposed to low level chemical warfare agent, mustard Gas. Ann Epidemiol, 000; 10: -8. ST 1- Rice P.Sulphur mustard injuries of the skin. Pathophysiology and management. Toxicol Rev 00; : Herman SM. et al. Antihistamines in the treatment of Atopic Dermatitis. J. Cutan Med Surg 00; Nov Malgorzata K. et al. Pruritus in advanced internal diseases, pathogenesis & treatment. The Netherlands J of Med 001; 8: Simon FER. et al. The pharmacology and use of H 1 receptor antagonist drugs. New England J of Med 1994;,0: Bruce M. et al. Comparative efficacy of antihistamines in Allergic Rhinitis and Urticaria. Clinical & Applied Immunology Reviews 001; Corren J. et al. Differentiating second-generation of antihistamines in the management of Allergic Rhinitis. Clinical Courier 000; 18: Grant JA. et al. A double-blind, single dose, crossover comparison of cetirizine, epinastine, fexofenadine, terfenadine and loratadine versus placebo. Allergy, 1999; 54: Masata F. et al. Effectineness of cetirizine & epinastine on the skin response to histamine iontophoresis. J. Dermatol Science 001; 5: Arnold AJ, Simpson JG, Jones HE, Ahmed AR. Suppression of histamine-induced pruritus by hydroxyzine and various neuroleptics. J Am Acad Dermatol, 1979, 1: Green S. et al. Double-blind, crossover study comparing doxepine with diphenhydramine for the treatment of urticaria. J Am. Acad Dermatol 1985; 1: Balaskas EV, Bamihas GI, Karamouzis M, Voyitasis G, Tourkantonis A. Histamine and Serotonin in Uremic Pruritus: Effect of Ondansetron in CAPD-Pruritic Patients. J. Nephron, 1998; 78: Yang T, Breen TW, Archer D, Fick G. Comparison of 0.5 mg and 0.1 mg intrathecal morphine for analgesia after Cesarean section. Can J Anaesth. 1999; 46:

6 %:G- & )F6,"Q Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M.Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol ; 86: Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebocontrolled, parallel-group study. Br J Dermatol 00; 148: Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 15: Nordness M, et al. High Dose Cetirizine: A Case Report. Cutis 00; 71: Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol, 004; 11: Simons FE, Sussman GL, Simons KJ. Effect of the H-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1- antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol, 1995; 95: Diepgen TL. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 00; 1: Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther, 199; 14: Lambert D, Hantzperg M, Danglas P, Bloom M. Double-blind comparative study of terfenadine and cetirizine in chronic idiopathic urticaria. Allerg Immunol (Paris) 199; 5: Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a nonsedating antihistamine. Br J Dermatol 1988; 119(1): Estelle F, Simons R. Advances in H 1 - Antihistamines. NEJM 004; 51: Dillman JF, Hege AI, Phillips CS, et al. Microarray analysis of mouse ear tissue exposed to bis-(- chloroethyl) sulfide: gene expression profiles correlate with treatment efficacy and an established clinical endpoint. J Pharmacol Exp Ther 006; 17: Simpson R, Lindsay CD. Effect of sulphur mustard on human skin cell lines with differential agent sensitivity. J Appl Toxicol 005; 5:115-8.